COVID-19 boosters offered to anyone ages 18 and older

Translate to Spanish or other 102 languages!

Image for illustration purposes.

Mega Doctor News

- Advertisement -

RIO GRANDE VALLEY, Texas – UT Health RGV is now offering COVID-19 boosters (Pfizer-BioNTech and Moderna) to anyone ages 18 and older.

All fully vaccinated people aged 18+ can get a booster at least 6 months after their second dose of Pfizer or Moderna or at least 2 months after initial dose of Johnson & Johnson.

Community members aged 5+ can get vaccinated at the following locations:

- Advertisement -

EDINBURG

Tuesday, Nov. 30, 1-6 p.m.

HARLINGEN

Wednesday, Dec. 1, 1-6 p.m.

- Advertisement -

MISSION

Wednesday, Dec. 1, 1-6 p.m.

  • V Express Care by UT Health RGV (at H-E-B plus!), located at 2409 East Expressway 83. (By appointment only – call for available dates and times at 956-296-2935.

FOR PARENTS AND GUARDIANS OF CHILDREN AGED 5-11

  • You willreceive a call from 1-833-888-2268 (1-833-UTVACN8 ) upon scheduling your child’s appointment. Please save this phone number 
  • This lower-dose Pfizer vaccine is the only COVID-19 vaccine to be authorized and recommended for use in children aged 5-11 years and should be administered as a two-dose series, three weeks apart — just as it is for people aged 12 and up.
  • Appointments for patient’s second dose will be scheduled on-site. 
  • All children under age 18 must be accompanied by a parent or guardian.

To make an appointment, log onto uthealth.org/vaccine or call 1-833-UTRGVMD.  

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

STHS Dedicating Latest “South Texas Healthy Living” Episode to Arthritis Education, July 26th

More than 58 million U.S. adults are living with doctor-diagnosed arthritis, according to the Centers for Disease Control and Prevention (CDC), making it the nation’s leading cause of disability.

No More Needles: FDA Approves First Daily Pill to Replace Injectable Cholesterol Drugs

The U.S. Food and Drug Administration approved Lipfendra (enlicitide), the first oral inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9), as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C), or “bad” cholesterol, in adults with hypercholesterolemia, including those with heterozygous familial hypercholesterolemia (HeFH). Image source: Merck.com.

STHS Heart Ranks Among Nation’s Top Hospitals for Heart Attack Care

Every year, more than 800,000 people in the United States suffer a heart attack, according to the Centers for Disease Control and Prevention, an event that occurs approximately every 40 seconds.

DHR Health Burn Surgeon Urges Public to Avoid Preventable Risks

Many of the most serious burn and trauma injuries can be prevented by avoiding unnecessary risks, according to Dr. R. Dewayne Edwards, chief burn surgeon, surgical critical care and trauma surgeon at DHR Health, who said public awareness and timely medical care remain essential to improving patient outcomes.
- Advertisement -